

TRIOCHEM PRODUCTS LIMITED

Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai,
Maharashtra, PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657
E-mail: info@amphray.com Website: www.triochemproducts.com
Corporate Identity Number: L24249MH1972PLC015544



Ref No: TPL PP 20251263 2025; 23rd February 2026

To
BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers, Dalal Street,
Fort, Mumbai: 400 001.

Security Code No. 512101 - ISIN No.: INE331E01013.

Dear Sir / Madam,

Sub: Re-Submission of Unaudited Standalone Financial Results for the Quarter and Nine months ended 31st December 2025

Re: Your email dated 20th February 2026 for Non-compliance with Regulation 33 of SEBI (LODR) Regulations, 2015 for the period ended December 31, 2025.

We acknowledge receipt of above refer email dated 20th February 2026 for the following observations:

Observations: 1. Standalone Results - Limited Review not submitted for Standalone Financial Result (Wrong Period Mentioned i.e December 31, 2024) for Quarter Ended - December 2025...

The Company is requested to submit complete financial results in PDF / XBRL format (applicable as per aforementioned observations) for the period ended December 31, 2025, at the earliest, failing which action may be initiated pursuant to the provisions of SEBI Master Circular. No. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 (erstwhile SEBI SOP Circular No. SEBI/HO/CFD/CMD/CIR/P/2020/12 dated January 22, 2020).

We would like to inform that there is typographical error in Limited Review Report for Standalone Financial Results for the Quarter Ended 31st December 2025 *now corrected (Wrong Period Mentioned i.e December 31, 2024)*

Now we are making re-submission for Unaudited Standalone Financial Results for the quarter and nine months ended 31st December 2025 along with Limited Review Report submitted by the Statutory Auditors of the Company are enclosed for your perusal and records. The Board of Directors of the Company at its meeting held on Friday, 13th February 2026 have inter-alia considered and approved the above result. The said financial results, duly signed by the, Mr.



[Handwritten signature]

TRIOCHEM PRODUCTS LIMITED

Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai,
Maharashtra, PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657
E-mail: info@amphray.com Website: www.triochemproducts.com
Corporate Identity Number: L24249MH1972PLC015544



Ramu S. Deora, Director was the Chairperson of the Board meeting held on 13th February 2026 and the authorized director to sign and submit the Said Financial Result.

Further we confirmed that, there is no change in Unaudited Standalone Financial Results for the quarter and nine months ended 31st December 2025 except typographical error in Limited Review Report for Standalone Financial Results for the Quarter Ended 31st December 2025 (Wrong Period Mentioned i.e December 31, 2024). We have made previous submission vide our letter reference number TPL PP 20251255 2025 dated 13th February 2026 vide acknowledgement number 12158424 dated 13-02-2026. Accordingly, we are now re-submitting complete financial results in PDF format (applicable as per observations) for the period ended December 31, 2025.

Please take the same in your record.

Thanking you,
Yours faithfully,
For TRIOCHEM PRODUCTS LIMITED


RAMU S. DEORA
CHAIRPERSON
DIN: 00312369
Encl.: as above

**RAMU
SITARAM
DEORA**
Digitally signed
by RAMU
SITARAM DEORA
Date: 2026.02.23
13:02:44 +05'30'



Kanu Doshi Associates LLP

Chartered Accountants


Independent Auditor's Review Report on Unaudited Quarterly and Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,

The Board of Directors of TRIOCHEM PRODUCTS LIMITED ("Company")

1. We have reviewed the accompanying statement of unaudited financial results of **TRIOCHEM PRODUCTS LIMITED ("Company")** for the quarter and nine months ended December 31, 2025 being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by SEBI from time to time.
2. The statement is the responsibility of the Company's management and has been approved by Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review of the Statement, which has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind As 34"), specified under Section 133 of the Companies Act, 2013, SEBI Circular CIR/CFD/PAC/62/2016 dated 5 July 2016 (hereinafter referred to as 'the SEBI Circular'), and other accounting principles generally accepted in India.
3. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information performed by Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards (Ind AS) and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Kanu Doshi Associates LLP
Chartered Accountants
Firm Registration No: 104746W/W100096



Kunal Vakharia
Partner
Membership No: 148916
UDIN: 26148916SNPTQF8020



Place: Mumbai
Date: February 13, 2026

3

TRIOCHEM PRODUCTS LIMITED

MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

 Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra,

PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657

 E-mail: info@amphray.com Website: www.triochemproducts.com

Corporate Identity Number: L24249MH1972PLC015544


TRIOCHEM PRODUCTS LIMITED

Registered Office : Sambava Chamber, 4th Floor, Sir P M Road, Fort, Mumbai - 400 001.

 Website: www.triochemproducts.com

CIN : L24249MH1972PLC015544

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2025

		(Rs in Lakh) Except EPS					
Sr. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31-Dec-25 (Unaudited)	30-Sep-25 (Unaudited)	31-Dec-24 (Unaudited)	31-Dec-25 (Unaudited)	31-Dec-24 (Unaudited)	31-Mar-25 (Audited)
1	Income						
	(a) Revenue from Operations	-	-	-	-	-	-
	(b) Other Income	22.06	29.52	45.85	73.68	72.54	105.01
	Total Income From Operations	22.06	29.52	45.85	73.68	72.54	105.01
2	Expenses						
	(a) Cost of Materials Consumed	-	-	-	-	-	5.29
	(b) Purchase of stock in trade	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	(d) Employees Benefit Expenses	14.44	13.76	29.53	41.72	44.24	58.88
	(e) Finance Costs	-	-	-	-	-	-
	(f) Depreciation and Amortisation Expenses	1.36	1.66	3.84	4.66	5.78	7.68
	(g) Other Expenditure	23.62	28.71	29.39	74.51	44.32	57.78
	Total expenses	39.42	44.13	62.76	120.89	94.34	129.63
3	Profit before exceptional items and tax	(17.36)	(14.61)	(16.91)	(47.21)	(21.80)	(24.62)
4	Exceptional items (refer Note 4)	-	-	-	-	-	-
5	Profit/ (Loss) before tax	(17.36)	(14.61)	(16.91)	(47.21)	(21.80)	(24.62)
6	Tax Expense						
	(a) Current tax	-	-	(22.33)	-	(22.33)	(11.86)
	(b) Deferred tax	(4.18)	4.65	(3.41)	(11.71)	(4.64)	27.25
	Total tax expenses	(4.18)	4.65	(25.74)	(11.71)	(26.97)	15.39
7	Net Profit/ (Loss) for the period	(13.18)	(19.26)	8.83	(35.50)	5.17	(40.01)
8	Other Comprehensive Income (Net of Taxes)						
	(A)(i). Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii). Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	(B)(i). Item that will not be reclassified to profit or loss	(34.31)	(64.87)	(40.70)	14.97	(1.36)	(66.82)
	(ii). Income tax relating to items that will not be reclassified to profit or loss	4.91	17.85	8.73	(2.12)	(8.30)	11.49
	Total other Comprehensive Income (net of taxes)	(29.40)	(47.02)	(31.97)	12.85	(9.66)	(55.33)
9	Total Comprehensive Income for the period	(42.58)	(66.28)	(23.14)	(22.65)	(4.49)	(95.34)
10	Paid-up equity share capital (Face Value of ₹ 10/- per share)	24.50	24.50	24.50	24.50	24.50	24.50
11	Other equity as per Balance Sheet of previous accounting year						1,342.19
12	Earnings per equity share (EPS) (of Rs. 10/- each) (not annualised)						
	Basic / Diluted EPS (in Rs.)	(5.38)	(7.86)	3.60	(14.49)	2.11	(16.33)



9

4

TRIOCHEM PRODUCTS LIMITED

MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra,

PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657

E-mail: info@amphray.com Website: www.triochemproducts.com

Corporate Identity Number: L24249MH1972PLC015544



TRIOCHEM PRODUCTS LIMITED

Registered Office : Sambava Chamber, 4th Floor, Sir P M Road, Fort, Mumbai - 400 001.

Website: www.triochemproducts.com

CIN : L24249MH1972PLC015544

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2025

Notes:	
1)	The above unaudited standalone financial results of the Company for the quarter and nine months ended 31st December 2025 have been reviewed by the Audit committee of the Board and approved by the Board of Directors at its meeting held on 13.02.2026. The same have been reviewed by the Statutory Auditors who have issued an unqualified conclusion thereon.
2)	The Unaudited financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India., as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI).
3)	The Company operates in single segment only, i.e. chemical and pharmaceuticals; therefore, disclosure requirement of Indian Accounting Standard (IND AS-108) "Segment Reporting" is not applicable.
4)	The Board of Directors, at its meeting held on 24th October 2025, has approved the proposal for the Sale of immovable properties, plant & machinery and investment property, of the Company situated in Maharashtra. The proposed sale constitutes a Material Related Party Transaction under the provisions of Section 188 of the Companies Act, 2013 and Regulation 23 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Accordingly, the approval of shareholders through postal ballot for the above transactions has been received on 13th December 2025. The said assets proposed to be sold have an aggregate written down value (WDV) of Rs.56.92 lakhs. The fair market value of the assets, as determined and certified by an Independent Registered Valuer, amounts to approximately Rs.672.05 lakhs for property, plant & machinery and Rs.509.00 lakhs for investment property. The consideration for the proposed sale shall be settled entirely in cash. As the shareholders' approval have been received, the said assets have been classified as 'Assets Held for Sale' in accordance with Ind AS 105 - Non-Current Assets Held for Sale and Discontinued Operations as notified under the Companies Indian Accounting Standards) Rules, 2015. The proposed transaction is at arm's length and in the ordinary course of business, aimed at monetizing non core assets. The proceeds from the sale are intended to be utilized for new business ventures and strategic initiatives to be undertaken by the Company. The completion of sale is expected to be concluded on or before 31st March 2026.
5)	The Corresponding figures of the previous quarter / year have been regrouped, recasted and reclassified to make them comparable wherever necessary.
FOR TRIOCHEM PRODUCTS LIMITED	
Place: Mumbai Dated: 13th February, 2026	 RAMU S. DEORA CHAIRPERSON DIN : 00312369



TRIOCHEM PRODUCTS LIMITED

MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

 Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra,

PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657

 E-mail: info@amphray.com Website: www.triochemproducts.com

Corporate Identity Number: L24249MH1972PLC015544



TRIOCHEM PRODUCTS LIMITED Registered Office: Sambava Chambers, 4th Floor, Sir P. M. Road, Fort, Mumbai - 400 001 website: www.triochemproducts.com CIN: L24249MH1972PLC015544						
--	--	--	--	--	--	--

(Rs. in lakhs) Except EPS

EXTRACT OF STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 31ST DECEMBER, 2025

Sr No	Particulars	Quarter Ended			Nine Months Ended		For the Year Ended on 31-Mar-25 Audited
		31-Dec-25	30-Sep-25	31-Dec-24	31-Dec-25	31-Dec-24	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	
1	Total Income from operations	22.06	29.52	45.85	73.68	72.54	105.01
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items)	(17.36)	(14.61)	(16.91)	(47.21)	(21.80)	(24.62)
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items)	(17.36)	(14.61)	(16.91)	(47.21)	(21.80)	(24.62)
4	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items)	(13.18)	(19.26)	8.83	(35.50)	5.17	(40.01)
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and other Comprehensive Income (after tax)]	(29.40)	(47.02)	(31.97)	12.85	(9.66)	(55.33)
6	Equity share capital (Face value Rs.10/- per share)	24.50	24.50	24.50	24.50	24.50	24.50
7	Other Equity						1,342.19
8	Earnings per share (of Rs.10/- each) (for continuing and discontinued operations)						
	a) Basic (not annualized)	(5.38)	(7.86)	3.60	(14.49)	2.11	(16.33)
	b) Diluted (not annualized)	(5.38)	(7.86)	3.60	(14.49)	2.11	(16.33)

Notes:

- The above unaudited standalone financial results of the Company for the quarter and nine months ended 31st December 2025 have been reviewed by the Audit committee of the Board and approved by the Board of Directors at its meeting held on 13.02.2026. The same have been reviewed by the Statutory Auditors who have issued an unqualified conclusion thereon.
- The Unaudited financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India., as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI).
- The Company operates in single segment only, i.e. chemical and pharmaceuticals; therefore, disclosure requirement of Indian Accounting Standard (IND AS 108) "Segment Reporting" is not applicable.
- The Board of Directors, at its meeting held on 24th October 2025, has approved the proposal for the Sale of immovable properties, plant & machinery and investment property, of the Company situated in Maharashtra. The proposed sale constitutes a Material Related Party Transaction under the provisions of Section 188 of the Companies Act, 2013 and Regulation 23 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Accordingly, the approval of shareholders through postal ballot for the above transactions has been received on 13th December 2025. The said assets proposed to be sold have an aggregate written down value (WDV) of Rs.56.92 lakhs. The fair market value of the assets, as determined and certified by an Independent Registered Valuer, amounts to approximately Rs.672.05 lakhs for property, plant & machinery and Rs.509.00 lakhs for investment property. The consideration for the proposed sale shall be settled entirely in cash. As the shareholders' approval have been received, the said assets have been classified as 'Assets Held for Sale' in accordance with Ind AS 105 - Non-Current Assets Held for Sale and Discontinued Operations as notified under the Companies Indian Accounting Standards) Rules, 2015. The proposed transaction is at arm's length and in the ordinary course of business, aimed at monetizing non core assets. The proceeds from the sale are intended to be utilized for new business ventures and strategic initiatives to be undertaken by the Company. The completion of sale is expected to be concluded on or before 31st March 2026.
- The Corresponding figures of the previous quarter / year have been regrouped, recasted and reclassified to make them comparable wherever necessary.
- The above is an extract of the detailed format of financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulation, 2015. The full format of consolidated financial results are available on the Stock Exchange website, www.bseindia.com and on the Company's website www.triochemproducts.com

FOR TRIOCHEM PRODUCTS LIMITED

 Place: Mumbai
 Dated: 13th February, 2026


 RAMU S. DEORA
 CHAIRPERSON
 DIN: 00312369

Date & Time of Download : 23/02/2026 13:04:32

BSE ACKNOWLEDGEMENT

Acknowledgement Number	12235124
Date and Time of Submission	2/23/2026 1:04:03 PM
Scripcode and Company Name	512101 - Triochem Products Ltd
Subject / Compliance Regulation	Re-Submission Of Unaudited Standalone Financial Results For The Quarter And Nine Months Ended 31St December 2025. Refer Your Email Dated 20Th February 2026
Submitted By	Puran Jaykisan Parmar
Designation	Designated Officer for Filing

Disclaimer : - Contents of filings has not been verified at the time of submission.